Publication Name	World Journal of Gastrointestinal Surgery
Manuscript ID	96057
Country	China

Received	2024-04-25 13:15
Peer-Review Started	2024-04-25 13:15
To Make the First Decision
Return for Revision	2024-08-18 05:38
Revised	2024-08-28 13:46
Second Decision	2024-09-14 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-14 07:04
Articles in Press	2024-09-14 07:04
Publication Fee Transferred	2024-09-15 16:08
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-09-19 02:41
Publish the Manuscript Online	2024-09-28 04:34

ISSN	1948-9366 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Randomized Controlled Trial
Article Title	Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Liang Wang, Yong-Zhi Diao, Xin-Fu Ma, Yu-Shuang Luo, Qi-Jing Guo and Xiao-Qian Chen
ORCID	Author(s) ORCID Number Liang Wang http://orcid.org/0000-0002-4206-5043 Yu-Shuang Luo http://orcid.org/0000-0002-1698-2614 Qi-Jing Guo http://orcid.org/0000-0001-5411-4247 Xiao-Qian Chen http://orcid.org/0000-0002-9699-5588
Funding Agency and Grant Number	Funding Agency Grant Number 2021 Key Topic of the Qinghai Provincial Health System-Guiding Plan Topic No. 2021-WJZDX-43
Corresponding Author	Xiao-Qian Chen, Doctor, Attending Doctor, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, West District, Xining 810000, Qinghai Province, China. cxq925@163.com
Key Words	Immune checkpoint inhibitors; Bevacizumab; Colorectal cancer; Cytotoxic T lymphocytes; Tumor-associated macrophages; Cancer-associated fibroblasts
Core Tip	In this study, immune checkpoint inhibitors (ICIs) in combination with bevacizumab were applied to microsatellite stable (MSS)/proficient mismatch repair (pMMR) colorectal cancer (CRC) patients with first-line treatment failure. It was found that ICIs combined with bevacizumab treatment significantly changed the tumor immune cells compared with the pre-treatment period. Additionally, ICIs combined with bevacizumab not only further improved their clinical efficacy compared with ordinary chemotherapy combined with anti-angiogenic drugs, but also yielded safe and controllable adverse drug reactions, which provided a new option for MSS/pMMR CRC patients experiencing 1st-line treatment failure.
Publish Date	2024-09-28 04:34
Citation	<p>Wang L, Diao YZ, Ma XF, Luo YS, Guo QJ, Chen XQ. Clinical evaluation of sintilimab in conjunction with bevacizumab for advanced colorectal cancer with microsatellite stable-type after failure of first-line therapy. <i>World J Gastrointest Surg</i> 2024; 16(10): 3277-3287</p>
URL	https://www.wjgnet.com/1948-9366/full/v16/i10/3277.htm
DOI	https://dx.doi.org/10.4240/wjgs.v16.i10.3277

Full Article (PDF)	WJGS-16-3277-with-cover.pdf
CONSORT 2010 Statement	96057-CONSORT-2010-statement.pdf
Manuscript File	96057_Auto_Edited_010816.docx
Answering Reviewers	96057-answering-reviewers.pdf
Audio Core Tip	96057-audio.mp3
Biostatistics Review Certificate	96057-biostatistics-statement.pdf
Clinical Trial Registration Statement	96057-clinical-trial-registration-statement.pdf
Conflict-of-Interest Disclosure Form	96057-conflict-of-interest-statement.pdf
Copyright License Agreement	96057-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	96057-foundation-statement.pdf
Signed Informed Consent Form(s) or Document(s)	96057-informed-consent-statement.pdf
Institutional Review Board Approval Form or Document	96057-institutional-review-board-statement.pdf
Non-Native Speakers of English Editing Certificate	96057-non-native-speakers.pdf
Peer-review Report	96057-peer-reviews.pdf
Scientific Misconduct Check	96057-scientific-misconduct-check.png
Scientific Editor Work List	96057-scientific-editor-work-list.pdf
CrossCheck Report	96057-crosscheck-report.png
CrossCheck Report	96057-crosscheck-report.pdf